Skip to Main Content
Table 2—

Glycemic parameters at the end of each treatment period

Glycemic parameter     Treatment sequencenBaselineTreatment
Difference (CSII − MDI)P
nCSIInMDI
Mean fructosamine (μmol/l)         
    CSII to MDI 50 351 ± 44 48 352 ± 46 49 360 ± 49   
    MDI to CSII 49 345 ± 48 50 334 ± 48 48 349 ± 50   
    Combined subjects  NA 98* 343 ± 47 97 355 ± 50 −11.8 [−13.4 to −4.63] 0.0001 
Mean AUC glucose ≥80 mg/dl (mb · h · dl−1)         
    CSII to MDI  NA 37 1,150 ± 758 34 1,605 ± 1018   
    MDI to CSII  NA 33 1,403 ± 713 37 1,718 ± 1,069   
    Combined subjects  NA 70 1,270 ± 742 71 1,664 ± 1039 −394 [−654 to −196] 0.0005 
Mean AUC glucose ≥140 mg/dl (mg · h · dl−1)         
    CSII to MDI  NA 37 381 ± 397 34 774 ± 721   
    MDI to CSII  NA 33 557 ± 496 37 779 ± 778   
    Combined subjects  NA 70 464 ± 452 71 777 ± 746 −313 [−489 to −150] 0.0004 
Daily insulin dose (units)§         
    CSII to MDI 45 42.3 ± 17.9 50 42.1 ± 19.2 46 46.0 ± 18.2   
    MDI to CSII 50 41.6 ± 16.1 48 39.6 ± 17.5 50 46.2 ± 20.5   
    Combined subjects 95 41.9 ± 16.9 98 40.9 ± 18.4 96 46.1 ± 19.4  0.08 
Glycemic parameter     Treatment sequencenBaselineTreatment
Difference (CSII − MDI)P
nCSIInMDI
Mean fructosamine (μmol/l)         
    CSII to MDI 50 351 ± 44 48 352 ± 46 49 360 ± 49   
    MDI to CSII 49 345 ± 48 50 334 ± 48 48 349 ± 50   
    Combined subjects  NA 98* 343 ± 47 97 355 ± 50 −11.8 [−13.4 to −4.63] 0.0001 
Mean AUC glucose ≥80 mg/dl (mb · h · dl−1)         
    CSII to MDI  NA 37 1,150 ± 758 34 1,605 ± 1018   
    MDI to CSII  NA 33 1,403 ± 713 37 1,718 ± 1,069   
    Combined subjects  NA 70 1,270 ± 742 71 1,664 ± 1039 −394 [−654 to −196] 0.0005 
Mean AUC glucose ≥140 mg/dl (mg · h · dl−1)         
    CSII to MDI  NA 37 381 ± 397 34 774 ± 721   
    MDI to CSII  NA 33 557 ± 496 37 779 ± 778   
    Combined subjects  NA 70 464 ± 452 71 777 ± 746 −313 [−489 to −150] 0.0004 
Daily insulin dose (units)§         
    CSII to MDI 45 42.3 ± 17.9 50 42.1 ± 19.2 46 46.0 ± 18.2   
    MDI to CSII 50 41.6 ± 16.1 48 39.6 ± 17.5 50 46.2 ± 20.5   
    Combined subjects 95 41.9 ± 16.9 98 40.9 ± 18.4 96 46.1 ± 19.4  0.08 

Data are means ± SD or difference [95% CI].

*

Numbers of subjects are greater than those who completed the trial because fructosamine was determined at an end- of-study visit; the last observation carried forward approach was used for fructosamine;

statistical inference was made for combined values only; treatment, sequence, and center were included as fixed effect, subject as random effect in the model;

AUC glucose was based on the first 24 h of CGMS monitoring; §treatment insulin dose values were measured after the 1-week dose adjustment period for each treatment period.

Close Modal

or Create an Account

Close Modal
Close Modal